home / stock / fnch / fnch news

FNCH News and Press, Finch Therapeutics Group Inc. From 03/31/22

Stock Information
Company Name: Finch Therapeutics Group Inc.
Stock Symbol: FNCH
Market: NASDAQ
Website: finchtherapeutics.com
Menu
FNCH FNCH Quote FNCH Short FNCH News FNCH Articles FNCH Message Board
Get FNCH Alerts

News, Short Squeeze, Breakout and More Instantly...
FNCH - Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel cla...
FNCH - Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus

Evogene acts as a computational biology technology hub; $50M market cap, $54M cash, 5 subsidiaries (4 of which are valuable). The article discusses subsidiaries Biomica, Lavie Bio and AgPlenus. Biomica's lead product BMC128, 4 strain live microbiome consortia in immuno-oncology, is pr...

FNCH - BioVie, Progenity top healthcare gainers; Nymox, HTG Molecular lead losers' pack

Gainers: BioVie (BIVI) +16%. Progenity (PROG) +16%. Kezar Life Sciences (KZR) +14%. Codiak BioSciences (CDAK) +13%. Ensysce Biosciences (ENSC) +10%. Losers: Nymox Pharmaceutical (NYMX) -29%. HTG Molecular Diagnostics (HTGM) -14%. Zhongchao (ZC...

FNCH - Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection

SOMERVILLE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics” or “Company”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® plat...
FNCH - Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit

SOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class...

FNCH - Tracking Seth Klarman's Baupost Group Holdings - Q4 2021 Update

Seth Klarman’s 13F portfolio value decreased from $10.88B to $10.13B this quarter. Baupost Group added Fiserv while dropping eBay and International Flavors & Fragrances. The portfolio continues to be heavily concentrated with the top three positions accounting for ~35% ...

FNCH - Finch Therapeutics Announces Additions to Senior Leadership Team

Bryan Gillis, MBA, appointed Chief Technology Officer Alka Batycky, PhD, appointed Chief Development Officer Howard Franklin, MD, MBA, appointed Senior Vice President, Late-Stage Development and GI Therapeutic Area Lead SOMERVILLE, Mass., Feb. 10, 2022 (GLOBE NEW...
FNCH - Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder

SOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel ...

FNCH - Finch Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference

SOMERVILLE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel ...

FNCH - Finch Therapeutics up 10% following large insider buy

Shares of Finch Therapeutics (FNCH +10.1%) are on the rise today after a director of the company and venture capital investor bought additional shares. Nicolas Haft, managing director of OMX Ventures, bought 63,850 shares at $10.18 on Dec. 20 according to an SEC filing. Following the transact...
Previous 10 Next 10